[Skip to Content]
[Skip to Content Landing]
June 20, 1953


Author Affiliations

Philadelphia; West Point, Pa.

From the Children's Hospital of Philadelphia and the Division of Virology, Department of Public Health and Preventive Medicine, School of Medicine, University of Pennsylvania (Drs. Drake, Barondess, Bashe, G. Henle, W. Henle, and Stokes) and the Department of Medical Research, Sharp & Dohme, Inc. (Dr. Pennell). Dr. Drake is Clinical Director of Vineland State School, Vineland, N. J., and Dr. Barondess is Research Fellow, Communicable Disease Center, and Dr. Bashe, Research Fellow, National Institutes of Health, U. S. Public Health Service.

JAMA. 1953;152(8):690-693. doi:10.1001/jama.1953.03690080034010

Reports on the efficacy of gamma globulin (immune serum globulin) prepared from normal adult human serum in the prevention of homologous serum hepatitis (viral hepatitis B), while indicating some prolongation of incubation period1 or some degree of protection against the disease in battle casualties who have been given transfusions,2 have provided evidence that this material is considerably less potent in prophylaxis against this disease than against infectious (epidemic) hepatitis (viral hepatitis A). In addition, a previous attempt1b to neutralize homologous serum hepatitis virus in icterogenic serum with 20 ml. of normal gamma globulin was unsuccessful. In view of the frequency and importance of the problem of homologous serum hepatitis, effective prophylactic measures would be of great value in making the administration of blood or blood products safer. Since there does not exist at present a satisfactory method for inactivation of hepatitis virus in these materials before injection,

First Page Preview View Large
First page PDF preview
First page PDF preview